Literature DB >> 3481328

In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients.

K G Naber1, D Adam, F Kees.   

Abstract

Studies in vitro showed that at concentrations of 1 and 4 mg/L ofloxacin inhibited 94 and 99% of the Gram-negative pathogens in isolates cultured from the urine of patients with complicated urinary tract infections (UTI). Against Gram-positive bacteria, 60 and 100% were inhibited at the corresponding concentrations. Comparisons of the MIC90 values of 8 quinolones showed the decreasing order of in vitro antibacterial activity to be ciprofloxacin, ofloxacin, norfloxacin, pefloxacin, enoxacin, pipemidic acid, nalidixic acid and cinoxacin. After an oral dose of ofloxacin 400mg, the mean peak serum concentration in 10 elderly patients was 5.5 mg/L and mean renal excretion during 24 hours was 41%. In 17 patients undergoing transurethral resection of the prostate, ofloxacin 400mg was given for perioperative prophylaxis. Two to 4.5 hours after administration, the median concentrations in prostatic secretion (5 patients) and prostatic adenoma tissue were 4.0 mg/L and 4.1 mg/kg, respectively. The corresponding serum concentrations of ofloxacin were 3.4 and 3.9 mg/L, respectively. In a group of 10 patients, 14.5 to 19.5 hours after oral administration of ofloxacin 400mg the median serum and prostatic adenoma tissue concentrations of ofloxacin were 1.9 mg/L and 1.2 mg/kg, respectively. The in vitro activity of ofloxacin concentrations attained in serum, urine, prostatic secretion and adenoma tissue show that it appears to be well suited for the treatment of complicated UTI.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481328     DOI: 10.2165/00003495-198700341-00011

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  3 in total

1.  Stomaching: a new concept in bacteriological sample preparation.

Authors:  A N Sharpe; A K Jackson
Journal:  Appl Microbiol       Date:  1972-08

2.  In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.

Authors:  K G Naber; F Sörgel; F Gutzler; B Bartosik-Wich
Journal:  Infection       Date:  1985 Sep-Oct       Impact factor: 3.553

3.  Ofloxacin: concentration in human ejaculate and influence on sperm motility.

Authors:  P Schramm
Journal:  Infection       Date:  1986       Impact factor: 3.553

  3 in total
  11 in total

Review 1.  The role of quinolones in the treatment of chronic bacterial prostatitis.

Authors:  K G Naber
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 2.  Role of quinolones in surgical prophylaxis.

Authors:  L A Mandell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 3.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 4.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

5.  Intraoperative concentrations of ofloxacin in serum, bile fluid, and gallbladder wall tissue.

Authors:  A Chin; M P Okamoto; M A Gill; D A Sclar; T V Berne; A E Yellin; P N Heseltine; M D Appleman
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 6.  Diagnostic and therapeutic problems in prostatitis. Therapeutic position of ofloxacin.

Authors:  J Aagaard; P O Madsen
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

Review 7.  Quinolones as a Potential Drug in Genitourinary Cancer Treatment-A Literature Review.

Authors:  Tomasz Kloskowski; Sylwia Frąckowiak; Jan Adamowicz; Kamil Szeliski; Marta Rasmus; Tomasz Drewa; Marta Pokrywczyńska
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

8.  Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid.

Authors:  K G Naber; M Kinzig; F Sörgel; D Weigel
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

Review 9.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

10.  Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers.

Authors:  S C Flor; M C Rogge; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.